Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s share price traded up 3.8% during trading on Thursday . The company traded as high as $12.90 and last traded at $12.89, with a volume of 103,791 shares. The stock had previously closed at $12.42.

A number of equities analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $30.00 price objective (up from $27.00) on shares of Paratek Pharmaceuticals in a research note on Friday, June 17th. Ladenburg Thalmann boosted their price target on Paratek Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, June 17th. Zacks Investment Research lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. Robert W. Baird reissued an “outperform” rating and issued a $40.00 price target (up from $30.00) on shares of Paratek Pharmaceuticals in a research note on Friday, June 17th. Finally, HC Wainwright boosted their price target on Paratek Pharmaceuticals from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, June 17th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $35.88.

The company’s 50 day moving average is $13.14 and its 200-day moving average is $14.45. The stock’s market capitalization is $291.66 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.03.

In related news, major shareholder Fund Iv L.P. Omega purchased 461,538 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, June 27th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Bigham purchased 20,000 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Thursday, June 23rd. The shares were bought at an average price of $13.45 per share, for a total transaction of $269,000.00. Following the completion of the transaction, the chief executive officer now owns 100,000 shares in the company, valued at $1,345,000. The disclosure for this purchase can be found here.

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.